{"filings":[{"id":2336997,"accession_number":"0001372514-26-000077","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-08-19T11:01:13+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Kiora licenses South Korean rights for KIO-301 to CKD for $1M upfront plus milestones and royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$1M upfront payment from CKD for exclusive South Korean rights to KIO-301 for retinitis pigmentosa and other ophthalmic indications.","Eligible for development, regulatory, and sales milestone payments plus double-digit royalties on net sales in South Korea.","CKD to handle development and commercialization in South Korea; partners Théa, Senju, and CKD to coordinate single global Phase 3 trial.","Kiora to focus on KIO-104 and ion channel modulators; evaluating strategic transactions to expand pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2115036,"accession_number":"0001372514-26-000075","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-08-07T11:03:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q2 2026 net loss $2.1M; cash $16.8M; ABACUS-2 higher-dose enrollment underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.1M vs $2.2M YoY; R&D expense $2.1M net of $1.3M Théa reimbursement; G&A flat at $1.4M.","Cash and short-term investments $16.8M at June 30, up from $13.9M at March 31; runway into late 2028.","Private placement secured for up to $24M gross, $5M upfront, remainder contingent on milestone-based warrant exercise.","ABACUS-2 Phase 2 (KIO-301) enrolling higher 100 µg dose cohort; last patient first visit Q1 2027, topline Q3 2027.","KIO-104 KLARITY Phase 2 enrolling higher-dose cohort; initial clinical data expected late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1120316,"accession_number":"0001372514-26-000063","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-06-18T11:02:51+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiora reports KIO-300 suppresses seizure activity in preclinical epilepsy model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KIO-300 significantly reduced epileptiform event frequency in hippocampal CA1 slices (p<0.0001).","Suppression persisted through treatment and washout; no impairment of normal electrical transmission.","Data presented at Epilepsy Foundation Pipeline Conference, June 18-19, 2026 in Leesburg, VA.","KIO-300 is the active ingredient of KIO-301, currently in Phase 2 for Retinitis Pigmentosa.","CEO cites broad therapeutic potential beyond ophthalmology; full rights retained outside eye."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":981489,"accession_number":"0001372514-26-000059","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-06-10T22:39:35+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Kiora shareholders approve 1.5M share increase to 2024 equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 1,500,000.","Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle re-elected as Class II directors with >1M votes for each.","Non-binding advisory vote on executive compensation approved: 1,019,325 for, 21,670 against.","Ratification of Haskell & White LLP as auditor for FY 2026: 2,358,943 for, 5,403 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92483,"accession_number":"0001372514-26-000048","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q1 cash $13.9M, $5.0M equity raise post-quarter; KIO-301 enrollment nearly 50% in Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 cash $13.9M; post-quarter raised $5.0M in equity from Perceptive Advisors; operational runway into late 2028.","Phase 2 ABACUS-2 enrollment for KIO-301 nearly 50% completed; trial sites expanding due to strong patient demand.","ABACUS-1 results published in Nature Medicine, validating KIO-301 photoswitch technology for vision restoration.","Phase 2 KLARITY study of KIO-104 progressing; safety review upcoming to enable dose escalation.","R&D expenses $2.1M with $1.2M Théa reimbursement; G&A $1.6M; collaboration receivables $1.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92482,"accession_number":"0001372514-26-000036","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals closes $5M private placement with Perceptive Advisors; warrants could add $19M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement raising $5.0M upfront; potential $19M from warrant exercise.","Sole investors: Perceptive Advisors and ADAR1 Capital Management; no placement agent engaged.","Each unit: 1 common share (or pre-funded warrant) + 4 Tranche A-1 + 1 Tranche A-2 warrants at $2.543.","All warrants exercisable at $1.94/share; A-1 term ≤9 months (30 days after strategic transaction), A-2 ≤4 years (30 days after Phase 3 enrollment).","Proceeds for general corporate purposes, including R&D and business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92481,"accession_number":"0001372514-26-000028","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals CDO Eric Daniels to resign April 17; successor search initiated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric J. Daniels resigns as Chief Development Officer effective April 17, 2026, to pursue other opportunities.","Resignation not due to any disagreement with company's operations, policies, or practices.","Company has initiated a search for Daniels' successor; CEO thanked Daniels for his contributions.","Kiora continues enrollment in KIO-301 (ABACUS-2) and KIO-104 (KLARITY) Phase 2 trials.","Safety reviews cleared for KIO-301 50µg and 100µg dose cohorts; KIO-104 enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103340,"accession_number":"0001372514-26-000025","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals reports FY2025 net loss of $10.8M; two Phase 2 trials underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.8M for 2025 vs net income of $3.6M in 2024 due to $16M upfront payment from Théa in prior year.","Cash, equivalents and short-term investments of $17.1M as of Dec 31, 2025; expects runway into late 2027.","KIO-301 Phase 2 ABACUS-2 trial for retinitis pigmentosa advancing; initial data readout expected Q3 2027.","KIO-104 Phase 2 KLARITY trial for macular edema dosing; non-cash impairment charge in Q4.","Executed option agreement with Senju for KIO-301 in Asia with potential value up to $110M plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119582,"accession_number":"0001372514-25-000079","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora reports Q3 net income of $27K; cash runway into late 2027; two Phase 2 trials enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $19.4M; collaboration receivables $1.2M; tax receivables $1.5M.","R&D expense $2.7M (net of $1.7M Théa reimbursement) vs $2.1M in Q3 2024.","Q3 2025 net income $27K vs net loss of $3.4M in Q3 2024, driven by tax impacts and noncash gains.","Both Phase 2 trials — KLARITY (KIO-104 for retinal inflammation) and ABACUS-2 (KIO-301 for retinitis pigmentosa) — continue recruitment and dosing.","Received $1.2M in reimbursed R&D from Théa in Q3; billed an additional $1.5M in the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136155,"accession_number":"0001372514-25-000068","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals furnishes updated investor presentation for H.C. Wainwright conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed 8-K on August 13, 2025 to disclose updated investor presentation (Exhibit 99.1).","Presentation prepared for H.C. Wainwright 5th Annual Ophthalmology Virtual Conference.","Company CFO Melissa Tosca signed the report as principal financial officer.","Data presented under Item 7.01 Regulation FD and not deemed filed for Exchange Act purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136154,"accession_number":"0001372514-25-000064","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q2 net loss $2.2M; initiated two Phase 2 retinal trials, Senju deal up to $110M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M in Q2 2025, flat YoY; cash and equivalents $20.7M, runway into late 2027.","KLARITY Phase 2 trial for KIO-104 in retinal inflammation initiated; patent exclusivity extended to 2043.","ABACUS-2 Phase 2 trial of KIO-301 for retinitis pigmentosa initiated with validated functional vision endpoint.","Option agreement with Senju for KIO-301 in Asia; potential deal value up to $110M plus royalties; $1.25M option fee received.","R&D expense $2.6M offset by $1.7M Théa reimbursement; G&A down to $1.4M from $1.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153223,"accession_number":"0001372514-25-000053","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Kiora shareholders elect directors, approve say-on-pay and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carmine Stengone and Brian M. Strem elected as Class I directors for three-year term.","Non-binding advisory vote on named executive officer compensation approved (1,144,829 for, 82,389 against).","Ratification of Haskell & White LLP as independent auditor for FY2025 passed (1,567,427 for, 78,598 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153222,"accession_number":"0001372514-25-000050","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Kiora grants Senju exclusive option for KIO-301 in Asia; $1.25M upfront, up to $110M milestones plus royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Immediate $1.25M option payment; if exercised, mid-single-digit million upfront and up to $110M in development, regulatory, and commercial milestones.","Tiered royalties from high single-digit to high teen percent on net sales; territory covers Japan, China, and other key Asian countries.","Option exercisable after topline data from ongoing ABACUS-2 Phase 2 trial; Senju to collaborate with Théa, Kiora's ex-Asia partner.","Combined deal value with Théa (2024) and Senju exceeds $400M plus royalties; cash runway extended into late 2027.","KIO-301 is a molecular photoswitch for retinitis pigmentosa and other inherited retinal diseases, currently in Phase 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153221,"accession_number":"0001372514-25-000045","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q1 net loss $2.2M; cash $24.1M into late 2027; initiates two Phase 2 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.2M vs net income $13.4M in Q1 2024 due to $16M upfront from Théa in prior year.","Cash & short-term investments $24.1M; runway extended into late 2027 beyond key data readouts.","Initiating Phase 2 KLARITY trial for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa); first patient enrollment expected Q2 2025.","Received $1.8M in reimbursed Q4 2024 R&D expenses from Laboratoires Théa; total $5.6M since collaboration began.","R&D expenses $2.5M (up from $1.7M) due to clinical trial activities; G&A $1.5M up from $1.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171996,"accession_number":"0001372514-25-000014","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora reports 2024 net income $3.6M; two Phase 2 retinal trials approved; cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Year-end cash, equivalents, and short-term investments $26.8M; expected runway into 2027.","Net income $3.6M in 2024 vs net loss $12.5M in 2023; Q4 2024 net loss $4.2M.","Received approval for KLARITY (Phase 2 KIO-104) and ABACUS-2 (Phase 2 KIO-301) studies.","Recognized $16M in collaboration revenue from Laboratoires Théa for KIO-301 in 2024.","Data readouts from both Phase 2 trials expected in 2026; first patient dosing in Q2 2025 for KLARITY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171995,"accession_number":"0001372514-25-000003","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Kiora formalizes employment agreements with CFO and CDO; base salaries $337K and $443K","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eric Daniels (CDO) receives $443,000 annual base salary, 40% bonus target, and $6,500/month relocation gross-up for 15 months.","Melissa Tosca (CFO) receives $337,000 annual base salary, 40% bonus target, and severance of 6 months' salary plus 0.5x max bonus.","Both agreements provide full equity acceleration upon a change of control and partial vesting on qualifying termination.","Daniels must reimburse 50% of relocation costs if he resigns or is fired for cause within 12 months.","Agreements executed January 10, 2025, effective January 1, 2025, for Daniels and formalizing Tosca's promotion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188988,"accession_number":"0001372514-24-000121","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q3 net loss $3.4M; cash $29M; advancing two Phase 2 retinal trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $29.0M at Sept 30, plus $1.8M collaboration receivables; runway into 2027.","Net loss $3.4M vs $5.8M in Q3 2023; decrease due to -$1.1M non-cash change in contingent consideration.","R&D expenses net $1.3M after $0.9M Théa reimbursement; G&A flat at $1.4M.","IND approved for ABACUS-2 Phase 2 study of KIO-301 in retinitis pigmentosa; first patient dosing in 2025.","Phase 2 KLARITY trial of KIO-104 designed; submission for approval on track for Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":16020000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188987,"accession_number":"0001372514-24-000117","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiora receives IND approval for Phase 2 trial of KIO-301 in retinitis pigmentosa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ABACUS-2 is a 36-patient, multi-center, double-masked, randomized, controlled Phase 2 trial.","Enrolling patients with ultra-low vision or no light perception regardless of gene mutation.","First patient dosing expected next year after validation of novel functional vision endpoints.","KIO-301 is a light-sensitive small molecule photoswitch targeting retinal ganglion cells.","Primary endpoints include safety, tolerability; key efficacy: functional vision and visual acuity tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205467,"accession_number":"0001372514-24-000105","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora reports Q2 net loss $2.2M, cash $27.8M; advancing two Phase 2 retinal trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $20K (grant); net R&D expense $0.9M after $1.1M TOI reimbursement credits.","Cash, equivalents and short-term investments $27.8M; plus receivables/Tax credits $3.7M; runway into 2027.","Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa design finalized; initiation expected 2H 2024.","Phase 2 CLARITY trial of KIO-104 for retinal inflammation planned to start 1H 2025, building on Phase 1b.","Melissa Tosca promoted to CFO; Lisa Walters-Hoffert appointed to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":2.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":16020000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205466,"accession_number":"0001372514-24-000099","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kiora Pharma receives EU orphan designation for KIO-301 in inherited retinal dystrophies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA grants Orphan Medicinal Product Designation for KIO-301 in non-syndromic rod-dominant retinal dystrophies including retinitis pigmentosa.","Provides at least 10 years of market exclusivity in Europe, reduced fees, centralized approval, and EMA scientific advice.","KIO-301 already has US Orphan Drug Designation; Phase 2 ABACUS-2 trial expected to initiate later in 2024.","KIO-301 is a small molecule photoswitch designed to restore light sensing in degenerated retinas, a non-gene therapy approach.","Co-development and commercialization partner Théa Open Innovation covers ex-Asia territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205465,"accession_number":"0001372514-24-000068","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kiora appoints Walters-Hoffert to board, promotes Tosca to CFO, regains Nasdaq compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa Walters-Hoffert appointed independent director and audit committee chair; Kenneth Gayron resigned.","Melissa Tosca promoted from EVP of Finance to CFO; salary raised to $337,000, bonus target to 40%.","CEO Brian Strem's salary increased to $569,000 (55% bonus); Chief Development Officer Daniels to $443,000 (40%).","New non-employee director compensation: initial 1,778 stock option grant, cash retainers up to $70,000 annually.","Regained compliance with Nasdaq minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)) as of June 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222390,"accession_number":"0001372514-24-000057","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals announces 1-for-9 reverse stock split effective June 11, 2024 to meet Nasdaq bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-9 reverse stock split filed June 6, 2024; effective at open of market on June 11, 2024.","Outstanding shares will reduce from ~26.7M to ~2.97M; fully diluted from ~100.1M to ~11.1M.","Class D warrants for 3.43M shares expired on June 6, 2024; other warrants adjust proportionally.","No change to authorized shares, par value ($0.01), or ticker (KPRX); fractional shares paid in cash.","Reverse split is intended to maintain compliance with Nasdaq minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222389,"accession_number":"0001372514-24-000054","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Pharma Q1 net income $13.5M on $16M TOI revenue; $31.3M cash; KIO-301 Phase 2 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Ended Q1 with $31.3M cash plus $1.8M R&D tax credits; runway over 2 years.","Revenue $16M from Théa Open Innovation upfront; net income $13.5M vs. $1.9M loss YoY.","Phase 2 ABACUS-2 trial for KIO-301 (retinitis pigmentosa) on track for Q4 2024 start.","Phase 2 trial for KIO-104 (retinal inflammation) expected to begin in 2025.","TOI deal includes up to $285M milestones and tiered royalties up to low-20% on sales."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":16000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222388,"accession_number":"0001372514-24-000039","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Kiora shareholders approve reverse stock split and increase authorized shares to 150M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of common stock approved at a ratio between 1-for-2 and 1-for-10; board will set exact ratio and timing.","Authorized common shares increased to 150,000,000 total authorized shares of all classes to 160,000,000 (including 10M preferred).","Issuance of up to 49,374,590 common shares upon exercise of Tranche A and B Warrants from February 2024 private placement approved.","Proposal to adjust voting requirements for certain future amendments failed to pass.","David Hollander, MD, MBA and Erin Parsons elected as Class III directors for a three-year term ending at 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241915,"accession_number":"0001372514-24-000027","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora reports 2023 net loss $12.5M; cash >$30M post partnership and placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.5M in 2023 vs $13.6M in 2022; R&D expense $4.0M, G&A $4.7M.","Cash and equivalents $2.5M at year-end 2023; $16M upfront from TOI partnership and $13.8M private placement net proceeds in Feb 2024 raised cash >$30M.","Company expects existing cash to fund operations through 2026.","KIO-301 Phase 2 trial in retinitis pigmentosa expected to start Q4 2024; KIO-104 Phase 2 planning underway.","Partnership with Théa Open Innovation grants exclusive rights to KIO-301 outside Asia; potential milestones up to $285M plus tiered royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241914,"accession_number":"0001372514-24-000013","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals furnishes updated investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate overview presentation dated H1 2024 under Regulation FD.","Presentation is available for use in investor meetings and web postings.","No financial results, clinical data, or operational changes were announced in the filing.","Ticker KPRX; the filing does not contain any guidance or material events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241913,"accession_number":"0001372514-24-000010","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals announces $15M private placement with potential $30M from warrant exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront gross proceeds of $15M from sale of shares and pre-funded warrants at $0.5524 per unit.","Tranche A warrants (24.7M shares, $0.6076 exercise) tied to KIO-301 Phase 2 data; Tranche B tied to KIO-104 Phase 2.","Participating investors include ADAR1 Capital, Nantahala Capital, Rosalind Advisors, Stonepine Capital, Velan Capital.","Net proceeds to fund KIO-104 development for posterior non-infectious uveitis and general operations.","Closing expected on or about February 5, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241912,"accession_number":"0001372514-24-000007","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Kiora licenses KIO-301 to Théa for up to $301M; $16M upfront, milestones, royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$16M upfront; up to $285M in milestones and tiered royalties up to low 20% on net sales.","TOI gets exclusive worldwide rights (ex-Asia) for retinitis pigmentosa and other ophthalmic uses.","Kiora responsible for Phase 2 design; TOI for Phase 3 and commercialization.","Phase 1/2 ABACUS data showed meaningful vision improvements; Phase 2 starts early 2024.","Investor webcast scheduled for Jan 31, 2024 at 5:30 pm ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241911,"accession_number":"0001372514-24-000002","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Kiora Pharmaceuticals receives Nasdaq extension to July 15, 2024 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq grants additional 180-day compliance period until July 15, 2024 for $1.00 minimum bid price rule.","Company failed to regain compliance by original deadline of January 15, 2024; stock below $1 since July 2023.","Extension conditioned on meeting market value of publicly held shares and other initial listing standards.","Company evaluating reverse stock split to cure deficiency; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259346,"accession_number":"0001372514-23-000160","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals furnishes updated investor presentation with no specific new facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed under Item 7.01 and 9.01; presentation provided as Exhibit 99.1.","No financial guidance, operational milestones, or clinical data disclosed in the filing.","The presentation may be used for investor meetings; content not detailed in this 8-K.","Ticker: KPRX; sentiment neutral due to lack of material new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259345,"accession_number":"0001372514-23-000159","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora expands KIO-301 Phase 2 development after positive ABACUS-1 results; Q3 net loss $5.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ABACUS-1 Phase 1b showed KIO-301 safe, tolerable, with significant visual field improvements and increased brain activity on fMRI.","Company plans Phase 2 trials for RP (ABACUS-2), Choroideremia, and Stargardt disease in 2024.","Q3 2023 net loss $5.8M vs $5.1M in Q3 2022; loss increase driven by non-cash impairment of KIO-101/201.","Cash and equivalents $5.4M, plus $1.3M tax receivables; runway into May 2024; $9.6M available on equity line.","Raised $6.3M in funding and $1.2M in tax incentives during first half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259344,"accession_number":"0001372514-23-000154","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Kiora's KIO-301 shows vision improvement in blind RP patients in Phase I/II trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Visual field increased significantly (p<0.05) at days 7 and 14; high-dose group gained 0.30 logMAR (3 lines) visual acuity.","Functional MRI showed increased brain activity in visual cortex; mobility test improvement from 24.7% to 60.0% at day 28.","No serious adverse events or retinal inflammation; duration of effect supports monthly IVT injection.","Company plans sham-controlled Phase II trial in 2024; will share ABACUS results with FDA in Q4 2023.","Patients with no light perception regained ability to perceive light; Odds Ratio 2.1-4.2 for light perception improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276611,"accession_number":"0001372514-23-000132","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiora shareholders approve 1M-share equity plan increase and >20% issuance to Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2014 Equity Incentive Plan approved, adding 1,000,000 authorized shares (1,872,064 for, 612,104 against).","Issuance of >20% of outstanding common stock to Lincoln Park Capital Fund, LLC approved under Nasdaq Rule 5635(d) (2,051,285 for, 432,684 against).","Adjournment proposal approved but not needed as prior two proposals passed (1,951,845 for, 526,462 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276610,"accession_number":"0001372514-23-000129","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Kiora Pharma appoints Praveen Tyle as Chairman; Paul Chaney retires after 17 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Chaney resigned as Chairman and Board member effective Sept 20, 2023; no disagreement cited.","Praveen Tyle, PhD, appointed Chairman effective same date; also serves as director.","Erin Parsons appointed Chair of Compensation Committee; Carmine Stengone joins Audit and Nominating Committees.","Tyle to help guide development of KIO-301 for retinitis pigmentosa and other inherited retinal diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276609,"accession_number":"0001372514-23-000125","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kiora adjourns Special Meeting to Sept 27 due to lack of quorum; only 23% voted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting on Aug 31 lacked quorum (needed 33.3% of shares); only 23% voted.","Meeting adjourned to Sept 27, 2023 at 8:30 a.m. PT; record date remains July 18, 2023.","Company hired proxy solicitor Alliance Advisors to help obtain quorum.","Proxies already submitted will be voted at adjourned meeting unless revoked; proposals unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276608,"accession_number":"0001372514-23-000118","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q2 net loss $2.6M; ABACUS phase 1b shows KIO-301 proof-of-concept in retinitis pigmentosa","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.6M in Q2 2023 vs $2.4M Q2 2022; cash $8.0M at quarter end.","Preliminary ABACUS data: KIO-301 safe/tolerable with positive vision impact; topline results expected Q4 2023.","Sharpened focus on rare retinal diseases; KIO-301 trials to expand to choroideremia and Stargardt's disease.","Shifted resources from KIO-101 (ocular RA) to KIO-104 (posterior uveitis); seeking partnerships for anterior segment programs.","Raised $6.3M funding extending runway to May 2024; received $1.2M in R&D tax credits from Australia and Austria."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276607,"accession_number":"0001372514-23-000112","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals appoints Carmine Stengone to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carmine Stengone (President & CEO of Pipeline Therapeutics) appointed as independent Class I director; term to 2025 annual meeting.","Stengone raised >$180M and executed a >$1B collaboration with Janssen; expertise in small molecules and neurodegenerative diseases.","He will advise on strategic decisions and clinical development, notably for KIO-301 (retinitis pigmentosa candidate in ABACUS trial).","Board determined independence under Nasdaq rules; compensation same as other non-employee directors.","No arrangements, family relationships, or material transactions with the company since start of last fiscal year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276606,"accession_number":"0001372514-23-000107","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Kiora receives Nasdaq deficiency notice for stock below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Bid price closed below $1.00 for 30 consecutive business days as of July 18, 2023.","Company has 180 calendar days, until January 15, 2024, to regain compliance.","To cure, closing bid price must be at least $1.00 for 10 consecutive trading days.","If not cured, Kiora may be eligible for a second 180-day period if other listing standards are met.","Company is evaluating options but cannot assure compliance or continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294375,"accession_number":"0001372514-23-000103","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiora Pharma 2023 annual meeting results: all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Kenneth Gayron, Aron Shapiro, Praveen Tyle elected as Class II directors (3-year term, through 2026).","Non-binding advisory vote on executive compensation passed: 243,595 for, 43,492 against, 8,996 abstain.","Ratification of Haskell & White LLP as independent auditor ratified: 798,689 for, 14,659 against, 19,738 abstain.","Total shares voted at meeting: approximately 1.1M (including broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294374,"accession_number":"0001372514-23-000101","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals eliminates $4.75M in milestone payments to Sentrx; grants animal health license for royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment cancels up to $4.75M in near-term milestones Kiora owed Sentrx under 2018 license.","Kiora grants Sentrx exclusive license to KIO-201 patents for veterinary use; Kiora receives low single-digit royalty on net sales.","Kiora retains optionality to source alternative manufacturing partners for KIO-201.","KIO-201 is a modified hyaluronic acid for persistent corneal epithelial defects, a rare disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294373,"accession_number":"0001372514-23-000097","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals closes $6.3M underwritten public offering, including full over-allotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $6.3M from offering of common stock, Series F convertible preferred, and Class C/D warrants.","Net proceeds to Kiora approximately $5.6M after underwriting discounts and offering expenses.","Underwriter's over-allotment option fully exercised, adding 750,000 common shares and warrants.","Series F preferred convertible into common; holder limited to 4.99% beneficial ownership (can increase to 9.99%).","Class C warrants expire in 5 years, Class D in 1 year; both have initial exercise price of $1.10 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294372,"accession_number":"0001372514-23-000070","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals reports Q1 net loss of $1.9M; positive clinical data for KIO-301, KIO-201, KIO-101","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $1.9M from $3.6M in Q1 2022; cash & equivalents $3.4M plus $1.7M R&D tax receivables.","KIO-301 (ABACUS trial) showed profound light perception improvements in a blind RP patient; full results by end 2023.","KIO-201 Phase 2 PCED trial met primary endpoint in 5 of 8 patients at 4 weeks; planning registration study.","KIO-101 Phase 2 OPRA trial first patient enrolled in April; targeting ocular surface disease from autoimmune conditions.","Approximately $9.6M available under equity line of credit; R&D expenses fell to $0.4M from $0.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294371,"accession_number":"0001372514-23-000057","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kiora's KIO-301 shows vision restoration in blind RP patients in Phase 1b","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Phase 1b ABACUS data: KIO-301 improved light perception in patients with no light perception.","Patient-reported light/dark contrast perception improved at days 7, 14, and 29 post-injection.","fMRI showed significantly increased V1 visual cortex activity at days 3 and 15 vs. baseline.","Quality-of-life score increased 6 points (clinically meaningful threshold is 2–4 points).","No adverse events reported; dose escalation and full results expected later in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314978,"accession_number":"0001372514-23-000053","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals dismisses EisnerAmper, appoints Haskell & White as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed EisnerAmper effective March 24, 2023 after competitive bid process.","No disagreements with EisnerAmper; material weakness in internal controls noted.","Prior audit report included going concern explanatory paragraph.","Appointed Haskell & White LLP as independent auditor for fiscal year 2023.","No prior consultations with Haskell & White on accounting matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314977,"accession_number":"0001372514-23-000051","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals reports FY2022 net loss of $13.6M; clinical milestones on track for 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.6M for FY2022, compared to $13.8M in FY2021; Q4 net loss $2.5M.","Cash and equivalents $6.0M at Dec 31, 2022, plus $1.4M in R&D tax receivables.","KIO-301 Phase 1b ABACUS trial enrollment ongoing; initial results at ARVO April 2023, topline by year-end.","KIO-201 Phase 2 PCED study topline results at ARVO; mean defect size reduction 90% (p<0.003).","KIO-101 Phase 2 trial initiation planned for Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314976,"accession_number":"0001372514-23-000010","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals Receives IND Approval for Phase 2 Study of KIO-101 for Ocular Autoimmune Disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Kiora received IND approval from FDA for Phase 2 study of KIO-101 for ocular surface disease in autoimmune patients.","Phase 2 trial will enroll ~120 patients in a multi-center, randomized, double-masked, controlled study assessing safety and efficacy.","Study expected to begin enrolling patients in Australia in first half of 2023; two concentrations (0.15% and 0.30%) will be tested.","KIO-101 is a topical DHODH inhibitor; systemic DHODH inhibitors generate ~$2B annually; target market ~3.43M U.S. patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314975,"accession_number":"0001372514-23-000008","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Kiora enters private placement ($200K gross) and $10M committed equity line with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 52,798 shares and 105,596 warrants at $3.788/share for $200K gross proceeds; warrants exercisable at $3.538.","Committed equity facility allows Kiora to sell up to $10M in common stock to LPC over 36 months at prevailing market prices.","Proceeds from both agreements to support clinical trials, working capital, and general corporate purposes.","LPC precluded from short-selling or hedging Kiora's common stock under the Purchase Agreement.","Kiora may terminate the Purchase Agreement at any time without cost or penalty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314974,"accession_number":"0001104659-23-002295","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiora updates pipeline; KIO-301 Phase 1b results expected 1H 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KIO-301 (RP) Phase 1b ABACUS trial first patient dosed Q4 2022; preliminary results expected 1H 2023.","KIO-101 (OPRA+) Phase 2 trial conditionally approved; first patient enrollment planned 1H 2023.","KIO-201 (PCED) Phase 2 trial fully enrolled Q4 2022; results and FDA registration dialogue expected 1H 2023.","Raised ~$20M gross in past 18 months; received $1.2M in R&D tax credits.","Appointed Melissa Tosca as EVP Finance; strengthened SEC reporting procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314973,"accession_number":"0001104659-23-000363","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kiora Pharmaceuticals moves headquarters to Encinitas, CA effective Jan 1, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective January 1, 2023, corporate headquarters relocated to 332 Encinitas Blvd, Suite 102, Encinitas, CA 92024.","Telephone number remains unchanged at (781) 788-9043.","Previous address was 1371 East 2100 South, Suite 200, Salt Lake City, UT 84105."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333327,"accession_number":"0001104659-22-120486","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Kiora raises $3.12M by reducing Class A warrant exercise price to $4.77, issuing new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.12 million from immediate cash exercise of 654,609 Class A warrants.","Exercise price of Class A warrants reduced from $8.00 to $4.77 per share.","New Inducement Warrants issued at $5.97 per share, exercisable after 6 months, term 18 months.","Ladenburg Thalmann acted as exclusive placement agent, receiving 8% of gross proceeds.","New warrants and underlying shares are unregistered, issued in a private placement under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-21T23:59:59+00:00|333327"}